|
|
Cancer Personalized Medicine 2008
Published: July 2008
Pages: 166
This is the latest most up-to-date Cancer Personalized Medicine Market Report from Select Biosciences. This report presents an up-to-date and thorough analysis of the Cancer Personalized Medicine Marketplace based upon Select Biosciences continuing industry coverage. Personalized Medicine, especially as it relates to Cancer, is undergoing significant growth and this report focuses in on the science, market/commercialization, and diagnostic/therapeutics trends in this space.
The Cancer Personalized Medicine marketplace represents the paradigm for personalized medicine market evolution and Select Biosciences focuses in this report on the various commercialized cancer predictor tests, their current status, traction in the marketplace, quantitative market opportunities, and the factors that are driving as well as challenging the expansion of this space.
Emerging classes of cancer biomarkers such as microRNAs and epigenetics are also examined in this report as well as the pipeline of RNAi-therapeutics for cancer. These biomarkers and treatment methodologies are drivers of the growth of the cancer personalized medicine marketplace for the future and therefore Select Biosciences provides coverage of these areas in this report—together with market participants making an impact in these particular areas.
Personalized Medicine marketplace is part of Select Biosciences continuous industry tracking and as part of this coverage; this report presents comprehensively the cancer personalized medicine market landscape in terms of:- Cancer Diagnostic Tests on the marketplace and in development that are developed as companion-diagnostics [coupled with a therapeutic regimen]
- Landscape of In Vitro Diagnostic Multivariate Index Assays [IVDMIAs]—multigene predictors with prognostic/predictive value
- Key Personalized Medicine Products in the Breast Cancer, Colon Cancer, etc. market spaces—together with the characteristics/features of These Products—HER2, oncotype DX™, MammaPrint®, UGT1A1, K-RAS, EGFR, etc.
- Worldwide market survey completed recently—June 2008—of qualitative and quantitative market trends/metrics in this space. Report purchasers receive access to all the raw data from the market survey via access to secure server from Select Biosciences as well as all the annotated/analyzed data in the report. This highly valuable and recently collected dataset is based on an extensive market analysis performed by Select Biosciences Industry Analyst Team—all the raw data and analyses based on the data are presented in the report
- Quantitative market forecast—for the year 2008 through 2011
- Comprehensive profiles of the various market participants in this space
- All report purchasers are entitled to 1 hour of free consultation with Select Biosciences Industry Analysts
Select Biosciences also includes in this report an overview of the drug metabolism and toxicity process, the role of specific cytochr
ome P450 (CYP450) enzymes, and how these impact personalized medicine.
Furthermore, in this report are presented an overview of the FDA-regulatory process on In Vitro Diagnostic Multivariate Index Assays (IVDMIAs), and how this impacts the market acceptance of the various cancer personalized medicine tests either in development or out in the market.
For more details about the scope of the industry coverage or specific topics that are presented in this report, please e-mail us at Kathy.Gray@Selectbiosciences.com.
Report Table of Contents [Downloadable PDF File]
Sample Pages from the Market Report [Downloadable PDF File]
Specific Topics Covered in this Report- Overview and Introduction to the Cancer Personalized Medicine Marketplace
- Thorough Market Analysis of the Cancer Personalized Medicine Space
- Breast Cancer Prognostic and Predictive Biomarkers
- All the Various Breast Cancer Companion Diagnostic Tests on the Market and in Development—Characteristics, Technology Platforms Utilized, Biomarkers Utilized, Features/Benefits, Addressable Patient Populations, Regulatory Status, Cost per Test
- Companion Diagnostics/Therapeutics for Other Cancer Classes—A Thorough Analysis Across the Market Landscape
- Warfarin Personalized Medicine as a Paradigm for the Personalized Medicine Marketplace—Biology, Markers Utilized, Landscape of Currently FDA-approved Tests
- Worldwide Market Survey of Cancer Personalized Medicine—Qualitative and Quantitative Market Metrics:
- Market Breakout by Types of Markers Currently Used
- Market Breakout by Types of Markers Forecast for the Future
- Challenges and Drivers of Market Adoption
- Market Opportunity for Cancer Personalized Medicine in Different Segments of the Cancer Marketplace
- Technologies Utilized in Different Cancer Segments in Companion Diagnostics
- Market Trends in microRNAs and Epigenetics as Cancer Diagnostic Biomarkers
- Market Forecast in Terms of Industry Revenues—2008 through 2011
- Emerging Trends in Cancer Biomarkers: MicroRNAs and Epigenetics
- Predicted Impact of microRNA-based Diagnostics and microRNA-based Therapeutics On Various Segments of the Cancer Marketplace
- RNAi-based Therapeutics Landscape for Cancer: Industry Participants, Biomarker Addressed, Status of Clinical Pipeline, Relevant Partnerships
- Comprehensive Set of Profiled Companies [Key Industry Participants]—see below
Companies Profiled in this Report- Abbott Molecular
- Affymetrix
- Agendia BV
- Celera
- Cepheid
- Clinical Data: PGXHealth, Cogenics, and Epidauros
- Dako Denmark A/S
- deCODE genetics
- DNA Direct
- DxS Ltd.
- Exact Sciences
- eXagen Diagnostics
- Gen-Probe
- Genelex
- Genentech
- Genomic Health
| - Genzyme Genetics
- Illumina
- Luminex
- Monogram Biosciences
- Myriad Genetics
- Nanogen
- Osmetech Molecular Diagnostics
- Perlegen Sciences
- PGxI Laboratories
- Prometheus Laboratories
- Roche Diagnostics
- Siemens Medical Solutions Diagnostics
- Target Discovery
- Third Wave Technologies
- Ventana/Roche
- XDx
|
Purchase report >>
|
|
|